Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced continued progress on its proprietary AI platform and robotics integration as it approaches initial commercial deployment. The company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing.

The advancement underscores Oncotelic’s commitment to leveraging cutting-edge technology to streamline drug development processes. By integrating vast amounts of scientific data with robotic automation, the company aims to reduce manual effort, accelerate research timelines, and enhance regulatory compliance. This could have significant implications for the biotech industry, where efficiency and accuracy are critical.

Oncotelic is primarily focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, contributing to a robust portfolio of inventions. The PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

For more information on Oncotelic’s latest news and updates, visit the company’s newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/2uitp.

This development comes as the biotech industry increasingly turns to artificial intelligence and automation to optimize drug discovery and manufacturing. Oncotelic’s integration of its AI platform with robotics could offer a competitive edge, potentially reducing costs and time-to-market for new therapies. The initial commercial deployment marks a significant milestone for the company, signaling a shift from research to practical application.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment.

The post Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment appeared first on citybuzz.